In tumorigenesis, the finely tuned acetylation status at the whole proteome level might be disrupted by dysregulated HDACs, and HDAC inhibitors could enable the re‐establishment of cellular acetylation‐deacetylation homeostasis, thus reversing cancer initiation and progression.12, 13. Here, HDAC9 is linked to cancer.